Pharmacy care perspectives on problems with HIV antiretroviral therapy in Sweden

Pharmacy World and Science

Volumn 29, Issue 4, 2007, Pages 412-421

  Jallow, Amadou ^a   Kälvemark Sporrong, Sofia ^b   Walther Jallow, Lilian ^c   Persson, Peter M ^c   Hellgren, Urban ^c   Ericsson, Örjan ^d  

^a Box 64 ^*  (Sweden)

^b Apoteket AB   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

Author keywords

Adherence; AIDS; Antiretroviral therapy; Concordance; Drug related problems; Drug use problems; HIV; Patient counselling; Pharmacy care; Pharmacy staff; Sweden

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; AWARENESS; CLINICAL PHARMACY; COMPARATIVE STUDY; CONTINUING EDUCATION; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HEALTH PERSONNEL ATTITUDE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT CARE; PATIENT INFORMATION; PERCEPTION; PUBLIC OPINION; STAFF; SWEDEN;

ANTI-HIV AGENTS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; FEMALE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PERCEPTION; PHARMACEUTICAL SERVICES; PHARMACISTS; PROBLEM SOLVING; PROFESSIONAL-PATIENT RELATIONS; QUESTIONNAIRES; SWEDEN;

EID: 34547558950     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9093-3     Document Type: Article

References (35)

1. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-9
4. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997; 277:1962-9
5. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977-83
6. Harrigan PR, Whaley M, Montaner JG. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999;13:F59-62
7. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30
8. Chesney M. Adherence to HIV medications. Clin Infect Dis 2000;30 (suppl 2):642-60
9. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34:407-14
10. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-505
11. Romano L, Venturi G, Giomi S, Pippi L, Valensin PE, Zazzi M. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. J Med Virol 2002;66:143-50
12. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32:18-29
13. Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, Squier C, et al. Adherence of human immunodeficiency virusinfected patients to antiretroviral therapy. Clin Infect Dis 1999;29:824-30
14. Barlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29(Suppl 1):S2-10
15. Schering Laboratories. Improving patient compliance: is there a pharmacist in the house? Schering Report XIV. Kenilworth, NJ: Schering Laboratories; 1992
16. Haddad M, Inch C, Glazier RH, Wilkins AL, Urbshott GB, Bayoumi A, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 2000;(3):CD001442
17. Knobel H, Carmona A, Lopez JL, Gimeno JL, Saballs P, Gonzalez A, et al. Adherence to very active antiretroviral treatment: impact of individualized assessment. Enferm Infecc Microbiol Clin 1999;17:78-81
18. Simoni JM, Frick P, Pantalone D, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Topics HIV Med 2003;11:185-98
19. Kansanaho HM, Puumalainen II, Varunki MM, Airaksinen MS, Aslani P. Attitudes of Finnish community pharmacists toward concordance. Ann Pharmacother 2004;38(11):1946-53. [Epub 2004 Oct 5]
20. Cote I, Gregoire JP, Moisan J, Chabot I. Quality of life in hypertension: the SF-12 compared to the SF-36. Can J Clin Pharmacol. 2004 Fall;11(2):e232-8
21. Bajramovic J, Emmerton L, Tett SE. Perceptions around concordance-focus groups and semi-structured interviews conducted with consumers, pharmacists and general practitioners. Health Expect 2004;7(3):221-34
22. Skoglund P, Isacson D, Kjellgren KI. Analgesic medication-communication at pharmacies. Patient Educ Couns 2003;51(2):155-61
23. Rosenqvist U, Höglund A, Nilsson JLG. Diabetes mass education for patients. Drug Inform J 1995;29:609-16
24. Lisper B, Nilsson JL. The asthma year in Swedish pharmacies: a nationwide information and pharmaceutical care program for patients with asthma. Ann Pharmacother 1996;30:455-60
25. Wade AH, Weir DN, Cameron AP, Tett SE. Using a problem detection study (PDS) to identify and compare health care provider and consumer views of antihypertensive therapy. J Hum Hypertens (2003);17:397-405
26. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: WHO; 2003. Available at: http://www.who.int/ chronic_conditions/adherencereport/en/. Accessed August 24, 2004
27. Rabkin JG, Chesney MA. Treatment adherence to HIV medications. In: Kalichman SC, editor. Psychosocial and public health impact of new HIV therapies. New York: Kluwer Academic/Plenum Publishers; 1999. pp. 61-82
28. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-77
29. Knobel H, Guelar A, Carmona A, Espona M, Gonzalez A, Lopez-Colomes JL, et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDS 2001;15:193-9
30. American Pharmacists Association. Medication compliance-adherence- persistence (CAP) digest. Washington, DC: APhA; 2003
31. Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc 2003;43:668-79
32. Hulka BS, Kupper LL, Cassel JC, Burdette JA. Communication, compliance, and concordance between physician and patients with their prescribed medications. Am J Public Health 1976;66:847-53
33. Sbarbaro JA. The patient-physician relationship: compliance revisited. Ann Allergy 1990;64:325-31
34. Bertholon DR, Rossert H, Korsia S. The patient's perspective on life with antiretroviral treatment: results of an 887-person survey. AIDS Reader 1999;9:462-9
35. Roberts KJ, Volberding P. Adherence communication: a qualitative analysis of physician-patient dialogue. AIDS 1999;13:1771-8